Fig. 2: Solved rate by country of origin.
From: Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness
The MYO-SEQ solved rate (in dark gray) was higher in countries such as Egypt and Turkey where the infrastructure for genetic testing for prescreening is not as widely available, and lower in Western European countries where genetic prescreening of common limb-girdle muscular dystrophy (LGMD) genes is routinely performed. Calculated for referring centers submitting more than 20 samples.
